Photo: taiwannews.com.tw
PharmaCorp Adjusts Q2 2025 Financials Following Auditor Review
PharmaCorp RX INC. has restated its Q2 2025 financial statement following an auditor review, impacting its working capital and transparency for investors on the TSX Venture Exchange.
- On October 10, 2025, PharmaCorp announced the refiling of its financial statements for the interim period ended June 30, 2025, reflecting necessary accounting adjustments.
- The adjustments to the financial statement were made after a comprehensive review by PharmaCorps Auditor, ensuring accurate reporting of the companys working capital.
- PharmaCorp, headquartered in Saskatoon, remains listed on the TSX Venture Exchange, and the amended Q2 2025 Statements are available on www.sedarplus.ca for public access.
Why It Matters
This restatement highlights critical issues in financial transparency within the pharmaceutical sector, affecting investor confidence and regulatory compliance, particularly for companies on the TSX Venture Exchange.